HC Wainwright Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price

TG Therapeutics (NASDAQ:TGTX) had its target price hoisted by HC Wainwright from $49.00 to $55.00 in a research note published on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2024 earnings at $0.15 EPS, FY2024 earnings at $0.07 EPS, FY2025 earnings at $1.17 EPS and FY2026 earnings at $1.77 EPS.

Several other brokerages have also recently issued reports on TGTX. The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday. B. Riley increased their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $37.67.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $28.81 on Tuesday. The company has a market cap of $4.46 billion, a P/E ratio of -288.07 and a beta of 2.19. TG Therapeutics has a 1-year low of $9.81 and a 1-year high of $28.92. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The stock has a 50-day moving average of $23.84 and a two-hundred day moving average of $20.46.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.65%. During the same quarter last year, the firm posted $0.73 EPS. The company’s revenue for the quarter was down 49.4% on a year-over-year basis. As a group, analysts anticipate that TG Therapeutics will post 0.13 EPS for the current year.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank grew its position in shares of TG Therapeutics by 0.5% in the 1st quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock valued at $4,321,000 after buying an additional 1,500 shares during the last quarter. Quantum Private Wealth LLC grew its holdings in shares of TG Therapeutics by 13.7% during the first quarter. Quantum Private Wealth LLC now owns 103,604 shares of the biopharmaceutical company’s stock worth $1,576,000 after purchasing an additional 12,523 shares during the last quarter. Sei Investments Co. acquired a new stake in shares of TG Therapeutics during the first quarter worth about $591,000. Russell Investments Group Ltd. lifted its holdings in shares of TG Therapeutics by 133.5% in the 1st quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock valued at $796,000 after purchasing an additional 29,923 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of TG Therapeutics by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 1,961 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.